Blogs

 

Latest News

Tuesday June 02, 2020

We welcome our new ASI Sustaining Member: CSL Behring

 

Our ASI Sustaining Members recognise the importance of supporting ASI and Immunology researchers in Australia and New Zealand. 

We are grateful and proud to introduce our newest ASI Sustaining Member: CSL Behring.

CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives.
 
Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 25,000 people, and delivers its life-saving therapies to people in more than 70 countries. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita.

Please join us in welcoming CSL Behring as an ASI Sustaining Member! 

Back to All Blogs